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Abstract 
Background: The assessment of health-related quality of life (HRQoL) in hepatitis C (HCV) 
infected individuals continues to gain importance.  However, rarely do reviews of this 
literature consider quantitative and qualitative accounts of HRQoL collectively, which only 
allows partial insight into the topic.  This narrative review aims to address this gap in the 
literature.  Methods: Literature searches were conducted using seven databases with two 
separate search strategies, and results assessed for eligibility using specific 
inclusion/exclusion criteria; a data extraction sheet was used to identify the dominant themes 
for each research paradigm which were then distilled to key findings to construct the 
narrative.  Results: Quantitative investigation reveals a low HRQoL in individuals with HCV 
due to a complex multifactorial cause.  During treatment for HCV, a further transient 
reduction is observed, followed by improvement if a sustained virological response is 
achieved.  Qualitative data provide a recognisable voice to the everyday challenges 
experienced by individuals with HCV including insights into diagnosis and stigmatisation, 
contextualising how a reduced HRQoL is experienced day-to-day.  Methodological 
limitations of these findings are then discussed.  Much of the quantitative data has little 
relevance to current substance users as they are excluded from most trials, and appraisal of 
the qualitative literature reveals a marked difference in the lived experience of HCV infected 
current substance users and that of other HCV groups.  Conclusion: Concurrent analysis of 
quantitative and qualitative paradigms provides a deeper understanding of the true burden of 
HCV illness on HRQoL.  Greater utilisation of qualitative research within international clinical 
guidelines is likely to be of benefit in identifying relevant HRQoL outcomes for substance 
users. 
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Background 
The latest reports estimate that worldwide between 130-150 million people are chronically 
infected with the hepatitis C virus (HCV), of which a significant number will go on to develop 
cirrhosis and hepatocellular carcinoma if left untreated (World Health Organisation, 2014).  
Within the UK, the most recent national estimates suggest around 214,000 individuals are 
infected (Public Health England, 2014), with injecting drug use continuing to be the most 
common route of viral transmission (Palmateer et al, 2013).  In recent years, dramatic 
advances have occurred in drug therapy for HCV with the arrival of Direct Acting Antivirals, a 
group of drugs which directly inhibit viral reproduction and have significantly improved 
treatment success rates (Conteduca et al, 2014).  Despite this, treatment uptake remains 
low, with UK estimates of approximately only 3-5% of those infected accessing antiviral 
therapy (Public Health England, 2014). 
 
With the historical move from a disease-centred model of medicine to a more 
biopsychosocial paradigm, a focus has emerged on not only the biomedical decrements of 
illness and curative benefits of treatment, but also the experience of illness and treatment 
from the patient perspective (Fayers & Machin, 2007); commonly termed ‘patient-reported 
outcome measures (PROMs)’.  Increasingly, this focus is being given central importance in 
the planning of future healthcare improvements (e.g. Scottish Government, 2010) and the 
licencing of new medications (Food & Drug Administration, 2009), however PROMs are also 
used to inform clinical practice, aiding interaction and communication with patients and 
clients on a one-to-one basis (Wu & Snyder, 2012).  Within the HCV research literature, the 
most commonly used quantitative PROM is Health-Related Quality of Life (HRQoL), a 
loosely defined term used to distinguish between aspects of life affected by disease or 
treatment for disease, and those broader quality of life issues such as access to green space 
within towns and cities (Fayers & Machin, 2007).  HRQoL is ordinarily measured by 
standardised psychometric questionnaires, most commonly the 36-item Short Form Health 
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Survey (SF-36) (Ware & Sherbourne, 1992), however there is no consensus on this survey’s 
exclusive use within HCV research, and numerous other tools also appear within the 
literature.  ‘Patient-reported outcome measures’ is an umbrella term used to encompass any 
report coming directly from a patient about their health condition or treatment however, and 
in this vein there is also a body of qualitative research which provides a more in-depth focus 
on HRQoL, by examining particular aspects of the lived experience (Miller et al, 2012).  
Arguably, these two bodies of research complement each other, with qualitative studies 
giving a recognisable voice to the decrements and improvements in HRQoL described in the 
quantitative work; however by their use of different methods and focus on different 
populations they may also generate distinct insights into different HRQoL perspectives. 
 
Existing reviews of the evidence in this area tend to focus on either qualitative or quantitative 
research and thus provide partial insight into the topic (e.g. Foster, 2009; Treloar & Rhodes, 
2009).  Miller et al (2012) did conduct a dual quantitative and qualitative systematic review of 
research published between 2000–2009, however did not compare the relative strengths 
and weaknesses of the findings produced by each paradigm and excluded interventional 
studies which contribute a large part of the quantitative literature in this area. The current 
review has been conducted to examine and synthesise the breadth of current research into 
HRQoL for people living with hepatitis C from both research paradigms. 
 
Methods 
The search strategy focused on seven databases; Medline, CINAHL, Embase, Cochrane 
Library, JBI COnNECT+, PsycINFO and ASSIA.  Two separate search strategies were 
developed to identify both quantitative and qualitative reports.  For quantitative papers, 
comparable search terms for ‘Hepatitis C’,  ‘Health-Related Quality of Life’ (including 
common abbreviated forms) and ‘Patient Reported Outcomes’ were used, accounting for 
variation in the Subject Index Terms specific to each search engine.  For qualitative papers, 
comparable search terms for ‘Hepatitis C’, ‘Quality of Life’ or ‘Life Experience’ and 
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‘Qualitative Research’ or ‘Interview’ were used, again accounting for variation in specific 
Subject Index Terms (the term ‘quality of life’ being used more generally within the 
qualitative literature than the more specific HRQoL).  In order to obtain papers that provided 
a detailed historical and contextual view as well as giving contemporary relevance, 
databases were searched to the extent of their temporal limits, preceding the publication 
announcing the isolation of HCV (Choo et al, 1989) in most cases.  Table 1 provides an 
example of the electronic search strategy conducted.  The search was not limited to only 
those papers which focused on HRQoL in HCV positive injecting drug users, as we sought to 
examine the comparative differences in HRQoL between this group and other HCV infected 
individuals, in addition to contrasting the way each research paradigm reveals this.  As the 
description of participants in studies varies (e.g. current injecting drug users, substance 
users, active injecting drug users, previous injecting drug users), often with little clarification 
of what these terms indicate, limiting the review by description of drug use status could also 
become specious and subjective.  The generic term ‘substance user’ has been used within 
this review, expect where injecting drug use is made explicit within the literature. 
 
Inclusion and Exclusion Criteria 
Figure 1 displays the results for the quantitative search strategy.  The initial 
inclusion/exclusion criteria used were as follows: inclusion criteria were adult participants, an 
English language abstract, and specific quantitative HCV HRQoL data provided.  Excluded 
papers were those dealing solely with other liver disease aetiologies, no HRQoL-related 
data, and papers concentrating on those undergoing haemodialysis or liver transplant, as 
these articles focused primarily on the impact of those specific interventions which is not the 
emphasis of this review.  Both observational and interventional studies were included, as 
were reviews at this initial stage.  Duplicate entries for the same article appearing in multiple 
search engines were removed.  One hundred and fifty one articles and 18 reviews were then 
recovered, including seven articles identified from reference lists.  Once examination of the 
reference lists was complete, review articles were then excluded as primary data sources. 
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The remaining retrieved articles were studied during which a further 30 papers were 
excluded for reasons shown in figure 1.  All the remaining 121 papers have informed this 
review and the main findings from this body of work are presented here.  Some of these 
references have not been further cited within the main text however for reasons of 
succinctness and economy.  Full details of the 121 papers can be found in supplementary 
file 1. 
 
Figure 2 demonstrates results for the qualitative search strategy.  The inclusion criteria were 
as follows: adult participants, an English language abstract, ‘life experience’ focus and 
qualitative data reported.  Exclusion criteria remained the same as the quantitative search 
strategy, and duplicate entries for the same article appearing in multiple search engines 
were removed.  Seventy three articles were then recovered, including five reviews and 
eleven articles identified from reference lists.  Review articles were then excluded as primary 
data sources.  The retrieved articles were studied during which eleven further exclusions 
were made for the reasons identified in figure 2.  All the remaining 57 papers have informed 
this review and the main themes from this body of work are presented here.  However, not 
all articles have been further cited within the main text, and full details are given of all 
references in supplementary file 2.  Records of all articles reviewed (n=178) were stored and 
managed online using RefWorks for both search streams.   
 
Analysis 
Data was extracted from each study by the lead author using a data extraction sheet which 
identified the author(s), date and source of publication, study design, key findings, limitations 
and recommendations, and inclusion of substance users.  Using these data key dominant 
themes were identified for each research paradigm, which provided the foundation for the 
formulation of results and the synthesis of a coherent narrative.  A narrative approach was 
adopted because of the variation in study design.  A narrative review summarises different 
primary studies into a comprehensive holistic overview of the topic, rather than addressing 
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specific questions.  Whilst narrative reviews are most commonly qualitative in nature, one of 
their strengths lies in drawing together the diverse understandings of a scholarly research 
topic (Jones, 2004) and therefore the approach fits this dual paradigm review well.  The main 
themes identified in the literature for each paradigm will be explored in a chronological 
manner, with causal investigation and HRQoL before, during and after HCV therapy focused 
on from the quantitative literature first, followed by examination of qualitative research 
concentrating on the experience of diagnosis through to the experience of HCV therapy. 
 
Results 
Causal Investigation: Virus-Related Factors 
The quantitative literature demonstrates HCV positive individuals have reduced HRQoL in 
comparison to healthy controls or population norms (Table 2) and goes onto investigate and 
debate the underlying cause for this.  Foster, Goldin and Thomas (1998) reported reduced 
HRQoL in patients with HCV which could not be attributed to either the degree of liver 
disease, or association with a history of injecting drug use, concluding the decrement was 
attributable to HCV per se.  Bonkovsky et al (1999) subsequently reported data from a large 
multi-centre drug trial which supported this hypothesis, concluding that HCV infection 
reduces HRQoL independent of comorbidities or factors associated with the virus.  These 
studies spearheaded research in this area, and results from more recent observational 
studies give weight to the argument that viral-factors contribute to HRQoL independent of 
host-factors (John-Baptiste et al, 2009; Strauss et al, 2014).  Whilst the mechanism for this is 
still debated, evidence of viral replication within the central nervous system adds weight to 
the argument (Forton et al, 2004). 
 
It is unlikely that any one factor is solely responsible for reduced HRQoL however, and a 
complex multifactorial cause is a more likely explanation.  Virus-related factors and 
associated extra-hepatic manifestations of HCV (such as cognitive impairment, fatigue and 
depression) compounded by host-related factors, psychiatric and medical co-morbidities and 
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the effects of stigma, are all likely to be significant contributors (Häuser et al, 2004; Helbling 
et al, 2008; Hsu et al, 2012).  These will now be examined. 
 
Causal Investigation: Host-Related Factors 
The role of illicit substance use in relation to HRQoL decrements is an important 
consideration, given the high incidence of current or former substance users within this 
patient population (Hutchinson et al, 2006).  Substance users experience a lower HRQoL 
than population norms irrespective of their HCV status (Dalgard et al, 2004; Gjeruldsen, 
Loge & Opjordsmoen, 2006; Fischer et al, 2013; McDonald et al, 2013), and former 
substance users who acquired the infection through injecting drug use have been shown to 
have lower HRQoL than individuals who acquired HCV by another route (Foster, Goldin & 
Thomas, 1998; Hollander, Foster & Weiland, 2006).  Interestingly, a study by Dalgard et al 
(2004) reported that active injecting drug users (IDUs) who believed they were infected with 
HCV had poorer HRQoL than those who did not or who did not know their status, 
irrespective of their actual serostatus, implying the knowledge (or assumed knowledge) of 
HCV positive status impacts HRQoL in addition to actually being infected with the virus.  This 
echoes earlier work from a much smaller sample which found people who injected drugs, but 
were unaware of their HCV positive status had better HRQoL than those who were aware of 
their infection 26 years after being infected (Rodger et al, 1999).  A recent much larger study 
from Scotland supports these findings.  McDonald et al (2013) assessed almost 3000 current 
IDUs accessing Injecting Equipment Provision Services in Scotland using the EQ-5D 
questionnaire and anonymised dried bloodspot testing, reporting a reduction in HRQoL 
between those who were aware of their HCV positive status and those who were not.  
Additionally, no difference in HRQoL was found between HCV negative IDUs and those who 
were HCV positive but unaware of their infection, supporting other work suggesting the 
impact of an undiagnosed HCV infection upon groups with already lower HRQoL than 
population norms places little additional burden, possibly due to the extent of co-morbidities 
present and overall lower HRQoL anyway (e.g. Schwarzinger et al, 2004; Thein et al, 2006).  
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In exploring the reasons for these findings however, it becomes evident that the quantitative 
data available fails to provide sufficient insight.  Why does undiagnosed HCV fail to impact 
on HRQoL for this population when it has been demonstrated to have a detrimental effect in 
other groups such as blood donors? (E.g. Strauss et al, 2014).  Is the negative ‘label’ of HCV 
constructed around preconceptions about the chronic nature of the virus and its historically 
poor treatment outlook, or from external influences such as societal stigma?  These points 
will be returned to in due course, when the qualitative literature surrounding the lived 
experience of HCV is examined. 
 
In addition to substance use, other comorbid psychiatric and medical problems have also 
been implicated in reducing HRQoL in HCV patients (Taliani et al, 2007; Hsu et al, 2012).  
Häuser et al (2004) argued that comorbidity is the best predictor of overall HRQoL reduction 
in patients with HCV, and further studies also highlight the importance of underlying medical 
and psychiatric comorbidities in reductions to both the mental health domains (Lim et al, 
2006; Snow et al, 2010) and the physical domains (Kwan et al, 2008) of HRQoL 
assessment. 
 
Causal Investigation: Stigma 
As already described, substance users who were aware of their infection had lower HRQoL 
than those who were unaware (Rodger et al, 1999; McDonald et al, 2013) which may be due 
in part to the effects of stigmatisation towards these individuals which negatively affect their 
social status and self-image (Rodger et al, 1999).  In one of the very few studies to combine 
a qualitative approach with a quantitative HRQoL assessment, Miller, Hiller and Shaw (2001) 
described patients’ distress by the perceived stigma associated with HCV, however without 
this qualitative adjunct the effect of stigma is poorly understood in the majority of HRQoL 
quantitative research.   
 
HRQoL Pre-Treatment 
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The impairment in HRQoL for individuals with HCV has been shown to be equivalent to, or 
more severe than, the impact on physical and general health experienced by patients with 
other chronic conditions such as hypertension, type II diabetes, arthritis or depression 
(Bayliss et al, 1998; Bonkovsky et al, 1999; Kallman et al, 2007) and has more impact on 
physical domains than hepatitis B in mono-infection (Foster, Goldin & Thomas, 1998; 
Bondini et al, 2007) and in HIV co-infected individuals (Gillis et al, 2013).  Of note, HCV also 
has a negative impact on mental health, an area in which detriments in other conditions are 
generally smaller (Foster, 2009; Tillmann et al, 2011). 
 
A reduction in HRQoL can occur even in the absence of cirrhosis or significant liver disease 
(Foster, Goldin & Thomas, 1998; Bonkovsky et al, 1999; Córdoba et al, 2003; Häuser et al, 
2004; Rowan et al, 2005; Helbling et al, 2008), and does not appear to be associated with 
Alanine Aminotransferase (ALT) levels (Foster, Goldin & Thomas, 1998; Miller, Hiller & 
Shaw, 2001; Arora et al, 2006; von Wagner et al, 2006; Helbling et al, 2008).  Where 
advanced significant liver disease does occur however, further reductions in HRQoL are 
reported on a sliding continuum from advanced bridging fibrosis, to compensated cirrhosis to 
decompensation (Córdoba et al, 2003; Bonkovsky et al, 2007; Kallman et al, 2007; 
Björnsson et al, 2009; Snow et al, 2010).  Although most HRQoL domains are affected, 
reductions in physical components are most frequently noted as being most sensitive to the 
negative impact of cirrhosis (Bayliss et al, 1998; Córdoba et al, 2003; Bonkovsky et al, 2007; 
Kallman et al, 2007; Mandorfer et al, 2014).  This low HRQoL in untreated HCV patients has 
been reported to have substantial economic costs to society, through loss of productivity, 
increased absenteeism from work and increased use of healthcare resources (El Khoury, 
Vietri & Prajapati, 2012; Liu et al, 2012). 
 
HRQoL During-Treatment 
The treatment of HCV has long been associated with a further transient reduction in HRQoL, 
largely attributed to the drugs used during therapy.  For example, patients treated with 
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Interferon-α (IFN) with or without ribavirin (RBV) demonstrated a significant increase in 
depression (Hunt et al, 1997), severe treatment-related distress (Bianchi et al, 2000) and a 
general decline in HRQoL during the period of therapy, which then returned to or surpassed 
baseline levels by 24 weeks post-treatment for those patients who achieved a Sustained 
Virological Response (SVR) (Ware et al, 1999; McHutchison et al, 2001).  With the 
pegylation of interferon (PEG-IFN) a reduced impairment in HRQoL and less fatigue were 
reported during PEG-IFN and RBV therapy compared to IFN & RBV, especially in the initial 
12-24 weeks, which had important implications for reducing treatment discontinuation 
(Bernstein et al, 2002; Rasenack et al, 2003, Hassanein et al, 2004, Mathew et al, 2006).  
The majority of these findings were from large multi-centre trials, however a similar pattern of 
transient decrement in HRQoL has also been described in observational cohorts (Kang et al, 
2005; Hollander, Foster & Weiland, 2006; Sinakos et al, 2010; Marcellin et al, 2011; 
Matsushita et al, 2014) and in HIV/HCV co-infection (Thein et al, 2007; Kemmer et al, 2012; 
Mandorfer et al, 2014). 
 
With the arrival of Direct Acting Antivirals (DAAs), HRQoL data has begun to be reported 
timeous alongside biomedical end points.  The polymerase inhibitor sofosbuvir was the first 
drug to have PEG-IFN free regimens reported in relation to HRQoL, which show significantly 
less impairment during therapy, although a modest decrement still remains during the 12 
week treatment duration (Younossi et al, 2014a; Younossi et al, 2014b).  As this data is 
exclusively from clinical trials it remains to be seen whether a similar scenario is observed in 
a patient population more representative of a typical clinical cohort; for example one 
including active substance users. 
 
HRQoL Post-Treatment 
For patients who achieve an SVR, benefits of treatment have been reflected in 
improvements to fatigue, and both physical and mental health domains of their HRQoL 
(Table 3).  The domains in which improvements are reported are not consistent however, 
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and indeed some studies have reported HRQoL remains significantly impaired following viral 
clearance with interferon therapy (e.g. Tillmann et al, 2011).  With the differences between 
results from the reported studies, it is important to examine the various limitations that may 
have influenced these findings. 
 
The time-point at which post-treatment HRQoL is measured could potentially influence the 
results obtained.  For example, Pojoga et al (2006) concluded that antiviral therapy does not 
improve HRQoL, however their post-treatment measurement was taken immediately after 
therapy had finished.  In contrast, a cross-sectional study by John-Baptiste et al (2009) 
reported that patients who had achieved an SVR had improved HRQoL at an average of 3.7 
years post-therapy.  The majority of studies have measured for improvement in HRQoL at 24 
weeks post end of treatment, a time when Helbling et al (2008) note that the positive 
emotional response due to treatment success is still strong and possibly influences 
responses.  More recently, measurement of SVR at week 12 post-treatment has been 
accepted as a primary end point for most clinical trials (Chen et al, 2013) with HRQoL data 
also collected at this time-point, possibly when the emotional response is even stronger, or 
the effects of treatment are still being felt. 
 
Another frequently reported limitation in the literature is that of patient awareness of their 
serological result prior to completion of the psychometric tools; do patients feel better, simply 
because they know they have now cleared the infection?  McHutchison et al (2001) argued 
that as changes in HRQoL are seen in different domains and not reported ‘across-the-
board’, it was unlikely that awareness of SVR was entirely responsible for the observed 
improvements.  A later study which blinded serological results to patients and investigators 
found improvements in mental health for patients who had undetectable HCV RNA at week 
12 of therapy compared to those who remained detectable (Quarantini et al, 2008), 
supporting the theory that knowledge of cure cannot account for all HRQoL increases alone.   
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As shown, the quantitative literature deals primarily with HRQoL cause and effect, reducing 
the burden of illness to numeric estimates which may demonstrate statistical and clinical 
significance, but the true patient experience, and the patient voice, remains silent.  It is with 
this in mind that we turn to the qualitative literature, and examine the main themes present in 
that body of work, beginning with the experience of diagnosis. 
 
Diagnosis 
A number of studies have drawn on the theory of chronic illness as biographical disruption 
(Bury, 1982) to provide insight into their participants’ narratives of diagnosis.  Medically, HCV 
is defined as a chronic infection if it does not spontaneously resolve within the first 6 months 
following acquisition (Seeff, 2002), however socially-constructed chronicity refers to a state 
of long-term pain and suffering that may not be ‘cured’ (Martin & Peterson, 2009).  For many, 
an initial reaction of shock was accompanied by overwhelming feelings of fear, denial, anger 
and depression following their HCV diagnosis (Glacken, Kernohan & Coates, 2001; 
Tompkins, Wright & Jones, 2005; Sutton & Treloar, 2007; Groessl et al, 2008; Janke et al, 
2008; Sgorbini, O’Brien & Jackson, 2009; Olsen, Banwell & Dance, 2012).  Faye & Irurita 
(2003) describe their participants feeling condemned, with their futures being forfeited: 
 
“It was a death sentence.  Not knowing a lot about it, and asking my doctor if I was 
going to die in ten years and he couldn’t tell me” (Faye & Irurita, 2003 p.94) 
 
In participants who had a history of injecting drug use, reactions to HCV diagnosis were 
sometimes modified and tempered, either because they suspected they were HCV positive 
anyway (Temple-Smith, Gifford & Stoové, 2004; Olsen, Banwell & Dance, 2012), or because 
of multiple HCV diagnoses within their peer group around the same time, providing context 
and mitigating the impact (Fry & Bates, 2012).  It also served as an unwelcome reminder of 
a previous time in their lives, potentially exposing an earlier identity that many had worked 
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hard to put behind them (Grundy & Beeching, 2004; Fry & Bates, 2012; Olsen, Banwell & 
Dance, 2012; Hill et al, 2014): 
 
“I was thrown right back there and it was awfully upsetting because I really did think 
that that time of my life was past and that I’d come to terms with grief and difficulty and 
all sorts of things in my life.  And what happened?  The legacy…” (Fry & Bates, 2012 
p.467) 
 
For individuals who had been experiencing significant symptoms of HCV such as 
unexplained fatigue, the intensely negative reaction to their HCV diagnosis also came with a 
sense of relief as their health problems had finally been formally identified and medically 
labelled (Glacken, Kernohan & Coates, 2001; Copeland, 2004; Groessl et al, 2008).  
Importantly, the reaction of current IDUs to an HCV diagnosis appears to be significantly less 
traumatic; not conforming to Bury’s (1982) notions and perhaps representing more 
‘biographical reinforcement’ (Carricaburu & Pierret, 1995) than ‘biographical disruption’.  This 
will be discussed in greater detail in due course. 
 
Following diagnosis, the re-evaluation of an individual’s life and an attempt to regain control 
are commonly reported.  Diagnosis can serve as a catalyst for the re-examination of life’s 
priorities (Glacken, Kernohan & Coates, 2001), attempting to integrate HCV into a 
comfortable, acceptable and balanced future life (Faye & Irurita, 2003).  A lack of information 
and understanding of HCV at diagnosis could hinder this process however, denying the 
sought after sense of control and exacerbating prognostic uncertainty (Glacken, Kernohan & 
Coates, 2001; Sutton & Treloar, 2007).  
 
The Lived Experience of HCV: Fatigue 
Fatigue is one of the most prevalent symptoms of HCV reported (Glacken, Kernohan & 
Coates, 2001; Glacken et al, 2003; Conrad et al, 2006; Groessl et al, 2008; Fry & Bates, 
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2012; Jiwani et al, 2013), and a greater understanding of how this impacts HRQoL starts to 
emerge when reviewing the qualitative data.  The fatigue experienced has been described 
as discernible from ‘normal fatigue’ and multidimensional in nature, perniciously impacting 
on physical, cognitive and affective dimensions, creating a whole body feeling of fatigue 
which is unrelieved by rest  (Glacken, Kernohan & Coates, 2001; Glacken et al, 2003): 
 
 “You cannot fight it; it is not a tiredness that you can fight like a normal tiredness.  A 
normal tiredness, you can fight it and get a second wind or if you had a few cups of 
coffee, it would keep you going.  None of this works with this tiredness” (Glacken et al, 
2003 p.247) 
 
The unpredictability of symptoms has also proved challenging.  A number of studies 
describe sporadic and episodic experiences of HCV illness (Conrad et al, 2006; Sutton & 
Treloar, 2007) which have a high impact on life when they occur, but when absent almost 
serve to reinforce a notion that the virus is not currently affecting health (Swan et al, 2010).   
 
The Lived Experience of HCV: Onward Transmission 
The possibility of passing the virus onto others has evoked strong reactions in a number of 
studies, with some participants citing it as a far greater HRQoL issue than any physical 
symptoms experienced (Conrad et al, 2006).  Women have discussed worries over vertical 
transmission to children (Temple-Smith, Gifford & Stoové, 2004; Conrad et al, 2006), which 
in addition to causing possible disruption to plans for a family, can also impact sex lives and 
relationships (Grundy & Beeching, 2004; Lenton et al, 2011; Jiwani et al, 2013).  The 
knowledge that HCV is contagious, and subsequent fear of transmission to others, forms a 
large part of the psychological impact of living with HCV, eliciting constant feelings of anxiety 
and sadness (Hill et al, 2014). 
 
The Lived Experience of HCV: Impact on Current IDUs 
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As previously mentioned, the reaction of current IDUs to an HCV diagnosis appears 
significantly less traumatic than those who stopped injecting many years ago and those who 
acquired HCV through another route.  A lack of shock following the diagnosis (Faye & Irurita, 
2003; Groessl et al, 2008; Harris, 2009) appears to be accompanied by a sense of 
inevitability linked to a high prevalence of HCV within their social networks (Sutton & Treloar, 
2007; Olsen, Banwell & Dance, 2012; Hill et al, 2014).  A commonly reported consequence 
of HCV diagnosis is an intense and overwhelming depression, however in current IDUs this 
has been described as shallow, and nothing to be dwelt on (Faye & Irurita, 2003) epitomised 
by a “what’s done is done, I can’t change it now…” (Tompkins, Wright & Jones, 2005, p.265) 
attitude.  Davis & Rhodes (2004) note that HCV is constructed as something acquired rather 
than caught among the IDUs they interviewed in London, language that implies transmission 
is unavoidable, normalized and almost acquired over time; a ubiquitous risk.  Wozniak et al 
(2007) explored this apparent normalization of HCV amongst IDUs in Canada, describing 
HCV as a defining characteristic of injecting drug use.  Further work from Australia reiterates 
these perceptions, with one study participant articulating her experience: 
 
“And nobody talked about hep C really.  I mean you know, in passing, it was just so 
assumed everybody had it.  And nobody saw it as a big deal.  No-one was thinking 
about it.  Nobody thought it was anything other than just a complete minor detail that 
had no bearing on life at all” (Harris, 2009 p.1032) 
 
Roy et al (2007) suggest that an HCV diagnosis could actually have a positive significance 
for some, as it enables the individual to feel just like everyone else in their situation, or “… 
one of the gang, like” (Roy et al, 2007 p.400).  These ambivalent views towards disease 
diagnosis are at odds with Bury’s (1982) account of biographical disruption, and instead 
appear to reinforce conceptions of self-identity and personal biography (Carricaburu & 
Pierret, 1995); HCV infection is synonymous with injecting drug use, and therefore injecting 
drug use will naturally lead to HCV infection (Olsen, Banwell & Dance, 2012). 
17 
 
 
HCV may also have limited impact on life, as the diagnosis can be lost in a sea of multiple 
disruptions.  In work with IDUs in Edinburgh, Copeland (2004) describes apathy towards 
having HCV perhaps stemming from multiple traumas faced in day-to-day life, and the 
significance of being HCV positive eclipsed by problematic existences and their identity as a 
‘problem drug user’.  If the severity of HCV in relation to other more immediate life-
threatening conditions (such as overdose) is considered, health problems that may not 
develop for many years such as those linked to HCV are unlikely to be overly concerning or 
prioritised, and activities that seek to improve an unimaginable future, such as HCV 
treatment, are not options worth investing in (Roy et al, 2007).  Williams (2000) astutely 
notes that biographical disruption is perhaps more keenly felt among the privileged rather 
than disadvantaged sections of society. 
 
As well as being contextualised within an individual’s life, a diagnosis of HCV is often 
described in relation to HIV/AIDS (Copeland, 2004; Davis & Rhodes, 2004; Cullen et al, 
2005; Tompkins, Wright & Jones, 2005; Roy et al, 2007; Wozniak et al, 2007; Munoz-Plaza 
et al, 2008; Harris, 2009; Swan et al, 2010; Lekas, Siegel & Leider, 2011).  HIV is often 
defined as the primary viral risk for injecting drug use, with the seriousness of HCV being 
undermined by HIV (Davis & Rhodes, 2004).  Excerpts from studies showing participants 
reactions at diagnosis serve to highlight this point: 
 
“I wouldn’t mind but I was in bits waiting for the results…the doctor was there going 
‘now…you have hepatitis C.’ I was there going ‘hurry up and tell me about the (HIV) 
virus’” (Cullen et al, 2005 p.74) 
 
“She told me ‘everything looks fine, except it’s written positive next to hepatitis C’.  So 
I said to her, ‘can I see? I hope I don’t have AIDS’” (Roy et al, 2007 p.400) 
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Even in HIV/HCV co-infection, a diagnosis of HCV can be over-shadowed by already having 
HIV (Copeland, 2004; Lekas, Siegel & Leider, 2011).  As public health harm-reduction 
messages for drug users historically centred on HIV prevention, HCV appeared within this 
framework later as an additional concern (Davis & Rhodes, 2004; Harris, 2009).  This ‘lesser 
of two evils’ perception appears to pervade, with HCV presented as relatively benign in 
comparison to HIV, and cited as a reason why further investigations and treatment are not 
accessed post diagnosis (Swan et al, 2010). 
 
The fact that HCV is often asymptomatic can also contribute to its low priority in lives with 
many competing demands.  Although fatigue, cognitive impairment and depression are 
known symptoms, these are not ubiquitous, and where they do occur may not always be 
attributed to HCV, particularly where there is co-morbid active substance use.  Due to the 
lack of physical impact there is no sense of threat from harbouring the virus (Fraenkel et al, 
2005) and it therefore becomes an insignificant part of people’s lives (Sutton & Treloar, 
2007).  Witnessing substance users ‘living normally’ and showing no signs of sickness can 
reinforce the normalization and social accommodation of HCV within social networks, 
psychologically and socially preparing other members for a potential diagnosis (Faye & 
Irurita, 2003; Carrier, LaPlante & Bruneau, 2005). 
 
Reviewing these narratives as a whole, it could be easy to construe that all current 
substance users are disinterested in their health.  However, despite repeated reports of an 
HCV diagnosis having little impact upon lives (Faye & Irurita, 2003; Sutton & Treloar, 2007; 
Olsen, Banwell & Dance, 2012), there are examples of individuals reacting badly to the news 
(Tompkins, Wright & Jones, 2005; Sutton & Treloar, 2007).  For some, an overwhelming 
sense of contamination has been described accompanied by a response characterized by 
despair (Fraser & Treloar, 2006).  Rather than focusing the individual to address the cause 
however (by potentially seeking treatment), a number of accounts relate a sense that the 
infection is now with them for life, and as such interest in their health may actually decrease: 
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“Oh what’s the use? You’ve got it, it’s not going to go away, what’s the use?” (Fraser 
& Treloar, 2006 p.106) 
 
“What’s the point? I’m either going to die from drugs or from liver disease” (Groessl et 
al, 2008 p.1961).  The authors note that immediately after diagnosis this participant 
began using drugs again. 
 
The Lived Experience of HCV: Stigma 
The preponderance of accounts detailing individuals’ experience of stigma in relation to 
HCV, create an overriding and pervasive theme within the literature on life experience, and 
again highlight its relative absence from the quantitative work.  The stigma experienced is 
multifaceted, incorporating a number of factors including the involvement of an infectious 
agent (Faye & Irurita, 2003; Conrad et al, 2006; Fraser & Treloar, 2006) and an association 
with HIV/AIDS (Zickmund et al, 2003), however the most frequently described association is 
with illicit injecting drug use (Faye & Irurita, 2003; Zickmund et al, 2003; Conrad et al, 2006; 
Paterson et al, 2006; Butt, Paterson & McGuinness, 2008).  This link to substance use is 
persistent and tenacious, and stigma and discrimination related to substance use have been 
experienced by many individuals with HCV irrespective of their mode of acquisition (Faye & 
Irurita, 2003; Butt, Paterson & McGuinness, 2008; Fry & Bates, 2012; Hill et al, 2014): 
 
“We are all tarred with the same brush.  People think ‘hepatitis’, yeah they’re all drug 
addicts, and they think ‘they’ve done something wrong’” (Hill et al, 2014 p.5) 
 
These stigmatising attitudes are encountered from family, friends, colleagues and also 
frequently within the healthcare setting (Miller, Hiller & Shaw, 2001; Zickmund et al, 2003; 
Grundy & Beeching, 2004; Temple-Smith, Gifford & Stoové, 2004; Tompkins, Wright & 
Jones, 2005; Butt, Paterson & McGuinness, 2008; Janke et al, 2008; Sgorbini, O’Brien & 
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Jackson, 2009; Fry & Bates, 2012; Jiwani et al, 2013; Hill et al, 2014).  Accounts from the 
literature also demonstrate an internalised stigma, whereby HCV positive individuals 
assimilate these widely held social views and describe feeling contaminated, dirty or ‘like a 
leper’ (Glacken, Kernohan & Coates, 2001; Miller, Hiller & Shaw, 2001; Zickmund et al, 
2003; Grundy & Beeching, 2004; Fraser & Treloar, 2006; Sutton & Treloar, 2007; Hill et al, 
2014). 
 
A decision not to disclose HCV positive status is often borne out of fears around subsequent 
stigmatisation (Glacken, Kernohan & Coates, 2001; Faye & Irurita, 2003; Tompkins, Wright 
& Jones, 2005; Conrad et al, 2006; Fraser & Treloar, 2006; Sutton & Treloar, 2007; Butt, 
Paterson & McGuinness, 2008; Sgorbini, O’Brien & Jackson, 2009; Jiwani et al, 2013; Hill et 
al, 2014), and can have a substantial impact on people’s lives, for example by not identifying 
oneself as HCV positive, the opportunity to obtain support is lost (Faye & Irurita, 2003; Hill et 
al, 2014).  In addition, any causal explanation for symptoms being experienced is removed, 
meaning individuals may have to continue working whilst extremely fatigued, or deny any 
emotional stress they may be suffering (Butt, Paterson & McGuinness, 2008; Fry & Bates, 
2012): 
 
“It requires a constant vigilance on my part not to let it slip…you always have to 
appear ‘normal’ regardless of how you are really feeling” (Glacken, Kernohan & 
Coates, 2001 p.110) 
 
Non-disclosure can have more wide reaching implications.  Butt, Paterson and McGuinness 
(2008) describe how one participant in their study quit his job and withdrew socially to 
conceal the diagnosis and associated symptoms.  Although this voluntary social withdrawal 
may seem an extreme reaction, it serves to illustrate the impact of deep-seated and 
entrenched discrimination towards individuals with HCV which pervades unchanged 
throughout the historic literature up to the present day.  Clearly, social isolation is not purely 
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a voluntary undertaking however, and Glacken, Kernohan and Coates (2001) describe the 
diagnosis of HCV resulting in participants feeling their ‘social identity’ had been stripped 
away, preventing them from maintaining previous social relationships.   
 
The Experience of HCV Treatment 
In addition to offering valuable insights into how HCV impacts on day-to-day life, the 
qualitative research also explores how the transient decrement in HRQoL reported in the 
quantitative literature is experienced, illustrating its impact on daily life and offering a greater 
depth of understanding.  The side-effects of IFN-based therapy are expounded with a clear 
patient voice, illuminating their intense and persistent nature and contextualising their impact 
on the individual.  These side-effects compromise employment opportunities and contribute 
to absenteeism (Hopwood & Treloar, 2005), affect physical appearance and changes in 
demeanour resulting in altered perceptions by others (Sheppard & Hubbert, 2006), and 
contribute to social isolation (Janke et al, 2008).  The persistence of these symptoms 
throughout the course of treatment, and the unpredictability of onset are also significant 
factors contributing to the reduced HRQoL experienced (Fraenkel et al, 2006).   
 
With insights into the lived experience of treatment and its side-effects, understandings into 
how these symptoms are managed and strategies for coping are also illuminated.  Hopwood 
& Treloar (2008) focused on Resilience Theory, describing participants drawing on past 
experience of drug dependence, their history and experience of living with a chronic illness 
and challenges and lessons learned from a socially disadvantaged life.  This theory is borne 
out in other studies, with examples of patients undergoing HCV treatment relating their use 
of anger management techniques learned at an alcohol treatment centre (Taylor-Young & 
Hildebrandt, 2009), and eschewing HCV support groups in favour of more familiar 12-step 
programmes previously attended (Sheppard & Hubbert, 2006).  In addition to resilience, 
support from friends and family is also a key factor in adherence to and continuation of 
treatment (Sgorbini, O’Brien & Jackson, 2009; Swan et al, 2010; Chapman & McManus, 
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2012), with recurrent reports of strong family support not uncommon in the literature 
(Sheppard & Hubert, 2006; Jiwani et al, 2013; Manos et al, 2013), although a mixture of 
positive and often very negative experiences in relation to friends and family are frequently 
described. 
 
Discussion 
As the experience of illness and treatment from the patient perspective continues to gain 
importance, this review has endeavoured to demonstrate the value of considering patient-
reported outcome measures from a variety of sources.  Psychometric instruments describe 
the health status of individuals at specific time points, providing valuable data to satisfy drug 
licensing requirements, and also providing quantifiable and accessible insights into HRQoL.  
These are beneficial for assessing cost utility and thus the economic benefits of an 
intervention.  However, much of this evidence comes from large randomised controlled trials 
(RCTs), whose participants are often unrepresentative of the larger HCV population, 
undermining ecological validity and generalizability (Britton et al, 1999; Van Spall et al, 
2007).  To illustrate this point, Beinhardt et al (2012) examined whether selection bias was 
observed within their clinical centre for patients who underwent HCV treatment through an 
RCT.  Those enrolled to an RCT had less advanced liver disease, less frequent history of 
psychiatric disorders and were less likely to be prescribed opioid-substitution therapy 
compared with those receiving routine care, which was largely driven by the studies 
exclusion criteria.  In another example, in a large RCT for patients being treated with 
telaprevir, Vera-Llonch et al (2013) reported trial participants’ baseline EQ-5D scores were 
actually higher than published US population norms making them not only unrepresentative 
of the HCV population, but of the general population as well.  These types of selection bias 
conspire to present evidence for HRQoL obtained under ‘ideal’ conditions, with far fewer 
reports on the effect in ‘real-world’ populations with HCV.   
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In addition to concerns regarding generalizability, there are also methodological difficulties 
with psychometric questionnaires measuring HRQoL.  Individuals with low literacy skills are 
frequently excluded from studies that develop and validate self-completed questionnaires 
(Jahagirdar et al, 2013) and within the field of HCV this has particular relevance, as it is 
estimated that up to 90% of those infected are current or former substance users 
(Hutchinson et al, 2006) who typically fall into this category.  The use of psychometric 
questionnaires has not therefore been validated in actively substance-using populations 
(Dalgard et al, 2004).  Further methodological difficulties including the complexity of 
choosing the correct tool, the lack of standardization across a condition-specific field, and 
the extent to which the chosen tool covers the concept being investigated have also been 
reported (Refolo et al, 2012).  For example, recent trials using direct acting antivirals in the 
treatment of HCV administered four separate questionnaires to their patients; a generic 
HRQoL survey, a disease-specific HRQoL survey, a questionnaire assessing the impact of 
fatigue, and one investigating impairment in daily activities and work productivity (Younossi 
et al, 2014a).  The sheer volume of paperwork involved in completing these questionnaires, 
and the time and concentration required to do so questions the quality of the information 
collected.  In addition, questionnaires may not capture the most pertinent concerns of the 
patient.  These instruments do not elucidate what strategies are employed by people to cope 
with any decrements to HRQoL they may experience, or explore the impact on behaviour 
and functioning in wider society. 
 
The qualitative literature therefore not only complements the quantitative HRQoL data, but 
also aids its interpretation.  For example, the insights gained into how HCV is viewed as a 
chronic illness help explain the variation in HRQoL observed in quantitative studies.  If living 
with HCV is considered along a chronic illness continuum, then a deeper insight into varying 
responses to psychometric assessments which are made at specific points in time is gained.  
Without this insight, it could be argued that compiling these responses and effectively 
reporting a ‘mean value’ has limited relevance and clinical application.  Indeed, this 
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approach also masks the disparity of reactions to diagnosis amongst current IDUs and other 
groups illuminated by the qualitative paradigm; a lower HRQoL is not necessarily 
experienced in the same way by all those it affects, which may have significant implications 
for engagement in treatment services.  Further, without accounting for the social 
stigmatisation HCV elicits (Paterson et al, 2007), the findings of most questionnaire-based 
HRQoL research are left open to conjecture.  Qualitative studies give a recognisable voice to 
the decrements and improvements in HRQoL described in the quantitative work, in addition 
to revealing more nuanced and deeper insights which also have important clinical 
significance.  The two bodies of research are therefore not only complementary, but 
essentially interconnected; the depth of understanding of the true burden of illness is absent 
unless qualitative accounts of the lived experience are reviewed concurrently alongside 
quantitative research.  An equivalent value should therefore be applied to this body of work; 
however there is a distinct disparity between their relative authorities. 
 
Quantitative HRQoL data is highly valued by policy makers, however reference to qualitative 
HRQoL research is largely absent from clinical management guidelines.  The Scottish 
Intercollegiate Guidelines Network (SIGN) (2013) reference HRQoL only once in their HCV 
management guidelines.  The European Association for the Study of the Liver (EASL) (2014) 
also contain one citation; and the American Association for the Study of Liver Diseases 
(AASLD & IDSA, 2014) address the issue briefly, but in slightly more detail through the 
context of extra-hepatic manifestations of HCV such as fatigue.  In documents aimed at 
guiding clinical practice, the omission of any significant input from HRQoL data highlights 
their medical focus; these are guidelines for the management of the hepatitis C virus, not the 
care of the patient. 
 
All of these guidelines are designed to assist clinical decision-making in order to optimise the 
management of HCV patients, however do so with little focus on how that management may 
affect the individual’s life, or indeed what the HCV positive individual’s priorities may actually 
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entail.  This seems contradictory to the biopsychosocial model of care; in which 
recommendations encompassing the management of the virus, should be combined with 
recommendations for humane treatment.  Addressing the impact of HCV on an individual’s 
HRQoL is perhaps as valuable as knowing the most efficacious drug combination to treat the 
virus, yet this focus is effectively absent from clinical guidance.  Some bodies, such as The 
Australasian Hepatology Association (2012) have produced nursing guidelines which begin 
to address this issue, however a more global multidisciplinary initiative would contribute to 
ensuring that HCV care remains patient-focused, and not entirely results driven in an age of 
care characterised by drug development.  It is also possible that as the influx of new 
treatments for HCV continues, decision-makers may ask that drugs be assessed not only on 
clinical efficacy or economic efficiency but also on humanistic outcomes (Gao et al, 2012). 
 
As with all syntheses of research, there are limitations to this review.  There is the possibility 
that relevant literature has been inadvertently omitted, however the search strategies aimed 
to account for this through the use of multiple databases and broad search terms.  
Publication bias may be evident due to the inclusion of interventional studies in the 
quantitative arm, however discussion of the limitations of these has been made, and to 
exclude these from the review could itself lead to a narrative bias considering their 
abundance within the literature.  To ensure all included articles were peer-reviewed, 
unpublished works were not included.  Within the qualitative narrative, the included studies 
were conducted in different settings with a diverse group of participants, however the 
identification of broad key themes purposefully aimed to transcend these limitations and 
focus on shared insights.  Finally, as previously mentioned, the variation in how drug use is 
reported within the published literature, and the lack of consensus on what constitutes 
‘substance use’ or ‘drug abuse’, and poor definition of the terms ‘active’, ‘current’ or 
‘previous’ drug use is problematic.  For the purposes of this review, supplementary files 1 
and 2 make explicit the inclusion criteria stated in individual studies, however further clarity 
around this matter would benefit the interpretation of this literature as a whole. 
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Conclusion 
Whilst the quantitative literature continues to report contemporary data on HRQoL with new 
treatment regimens (e.g. Younossi et al, 2014a), only one qualitative study reporting patient 
perspectives on HCV treatment since the advent of triple therapy has been published to date 
(Rasi et al, 2014), and as such a rounded contemporary understanding of HRQoL for 
individuals with HCV is absent.  This review aims to catalyse further qualitative research in 
this area and to provoke discussion into the greater use of all HRQoL data within the 
development of clinical practice guidelines. 
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Figure 1: Flowchart of included and excluded studies identified in the quantitative search strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Flowchart of included and excluded studies identified in the qualitative search strategy 
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Records excluded, including removal of 
duplicates 
n = 1203 
Full-text articles assessed for eligibility 
 
n = 169 
Full-text articles excluded 
 
n = 30 
• Editorial/Comment: 11 
• No English language version of full  
paper available: 2 
• HRQoL not main focus/data for 
HRQoL unavailable: 2 
• Evaluation of a specific 
psychometric instrument: 2 
• Conference abstract only: 10 
• Unpublished dissertation: 3 
 
Full text review articles excluded as 
primary sources 
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database searching 
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paper available: 1 
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Table 1: Example of the electronic search strategy used within the Medline database for both the quantitative 
and qualitative search strategies. No limits were applied, searches last conducted on 29.09.2014. 
 
 
Quantitative Search Strategy 
Number 
of 
Studies 
Qualitative Search Strategy 
Number 
of 
Studies 
Search Term
s (ST) or Subject Index 
Term
s (SIT) 
 
S1: Hepatitis C (SIT), OR Hepatitis C, 
Chronic (SIT) OR Hepatitis C (ST) 66,420 
 
S1: Hepatitis C (SIT), OR Hepatitis C, 
Chronic (SIT) OR Hepatitis C (ST) 
AND Quality of Life (SIT) OR Quality 
of Life (ST) OR Life Change Events 
(SIT) OR Experience (ST) 
 
2,248 
S2: Patient Outcome Assessment 
(SIT) OR Patient Reported Outcomes 
(ST) OR Quality of Life (SIT) OR 
Health-Related Quality of Life (ST) 
OR HRQL (ST) OR HR-QOL (ST) OR 
HRQOL (ST) 
65,897 
S2: Qualitative Research (SIT) OR 
Qualitative (ST) OR Interview, 
Psychological (SIT) OR Interview as 
Topic (SIT) OR Interview* (ST) 
348,448 
S3: S1 AND S2 319 S3: S1 AND S2 133 
 Application of initial 
inclusion/exclusion criteria 136 
Application of initial 
inclusion/exclusion criteria 43 
Further exclusions following retrieval 
of full articles 121 
Further exclusions following retrieval 
of full articles 36 
Number of studies excluding reviews 106 Number of studies excluding reviews 34 
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Table 2: Summary of all studies identified within the quantitative search arm (see supplementary file 
1) where the most commonly used tool was employed (SF-36), and data reported for HCV patients 
versus ‘healthy’ controls or population norms in the 8 SF-36 subscales is available.  ‘S’ indicates a 
reported statistically significant impairment compared with healthy controls or population norms. 
 
 
 
 
 
Author & Year n =
Bayliss et al (1998) 157 S S S S S S S S
Foster et al (1998) 72 S S S S S S S S
Bonkovsky et al (1999) 642 S S S S S S S S
Ware et al  (1999) 324 S S S S S
Bianchi et al (2000) 126 S S S S S S
Fontana et al (2001) 107 S S S S S S S
Hussain et al (2001) 220 S S S S S S S S
McHutchison et al  (2001) 912 S S S S S
Miller et al (2001) 95 S S S S S S S S
Kramer et al (2002) 100 S S S S S S S
Córdoba et al (2003) 120 S S S S S S
Gallegos-Orozco et al (2003) 157 S S S S S S S S
Dalgard et al (2004) 199 S S S S S S S S
Fleming et al (2004) 299 S S S S S S S S
Kang et al (2005) 182 S S S S S S
Kramer et al (2005) 120 S S S S S S S S
Rowan et al (2005) 62 S S S S S
Balfour et al (2006) 123 S S S S S S S S
Danoff et al (2006) 112 S S S S S S S S
Gjeruldsen et al (2006) 42 S S S S S S S
Hollander et al (2006) 147 S S S S S S S S
Lim et al (2006) 201 S S S S
Mathew et al (2006) 'responders ' 25
Mathew et al (2006) 'non-responsers ' 130 S S S S S S
Pojoga et al (2006) 35 S S Excluded S S S S S
Thein et al (2006) 267 S S S S
Bonkovsky et al (2007) 1144 S S S S S S S S
Kallman et al (2007) 130 S S S S S S S S
Taliani et al (2007) 'non-responders' 58 S S S S S S S
Taliani et al (2007) 'relapsers' 43 S S S S
Taliani et al (2007) 'untreated' 163 S S
Teixeira et al (2007) 'no liver biopsy ' 37 S S S S S
Teixeira et al (2007) 'liver biopsy ' 40 S S S S S S S
Teixeira et al (2007) 'for treatment ' 43 S S S S S S S S
Helbling et al (2008) 833 S S S S S S S S
Kwan et al (2008) 303 S S S S S S S
Batki et al (2009) 100 S S S S S S S S
Björnsson et al (2009) 472 S S S S S S
Hsu et al (2009) 271 S S S S S S S S
Karaivazoglou et al (2010) 39 S S S S S S S S
Sinakos et al (2010) 99 S S S S
Chang et al (2014) 108 S S S S S S
Kuwashiro et al (2014) 175 S
Matsushita et al (2014) 228 S S
Strauss et al (2014) 35 S S S S S S S
SF-36 Subscales
Role 
Physical
Physical 
Function Bodily Pain
General 
Health Vitality
Social 
Functioning
Role-
Emotional
Mental 
Health
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Table 3: Summary of all studies identified within the quantitative search arm (see supplementary file 1) comparing HRQoL in HCV patients (as measured by 
SF-36 or HQLQ) who achieve SVR compared to their baseline levels or non-responders.  Only studies where data for SF-36/HQLQ subscales has been 
reported are included.  ‘S’ indicates a reported statistically significant improvement compared to baseline levels or non-responders, ‘T’ indicates a trend 
towards (*indicates SVR12 reported). 
 
 
 
 
Author & Year n = Clinical 
Trial Data?
Physical 
Function
Role 
Physical
Bodily Pain General 
Health
Vitality Social 
Functioning
Role 
Emotional
Mental 
Health
PCS MCS Sleep Health-
Distress
CHC Health-
Distress
CHC 
Limitations
Bonkovsky et al (1999) 642  S S S S S
Ware et al (1999) 324  S S S S S S
McHutchison et al (2001) 912  S S S S
Bernstein et al (2002) 1441  S S S S S S S S S S
Desmorat et al (2003) 168 S S S S S S S S S S
Rasenack et al (2003) 531  S S S S S S S S
Hassanein et al (2004) 1121  S S S S S S S S S S
Perillo et al (2004) 412  T T
Kang et al (2005) 182 S S S S S S S S
Arora et al (2006) 491  S S S S S S
92 S S S S S S S S S S S S S
46 S S S S S S S S S S S S S
Dan et al (2006) 271 S
Hollander et al (2006) 147 S S S S S
Mathew et al (2006) 25  T
Pojoga et al (2006) 35
Bonkovsky et al (2007) 1144  S S S S S S
Thein et al (2007) 34 S S S S S S S S S
John-Baptiste et al (2009) 235 S S S S S S S S S S S S S
Sinakos et al (2010) 99 S S S T S S S
Marcellin et al (2011) 1860 S S
Bezemer et al (2012) 128  S S
Isaacs et al (2013) 118 S S S S S S
Jerkeman et al (2014) 40
Younossi et al (2014a)* 192  S
278  S
215  S S T
201  S T S S S
327  S S S
Younossi et al (2014c)* 334  S S S
SF-36 Subscales HQLQ Additional DomainsSF-36 Summary Scales
Younossi et al (2014b)*
Bini & Mehandru (2006) 
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